Dublin’s Jazz Pharmaceuticals has inked a cancer research collaboration potentially worth more than $4 billion plus royalties with AbCellera, the Vancouver biotech backed by billionaire investor and political activist Peter Thiel.
UK antifungal specialist F2G and Japanese partner Shionogi have announced positive topline results from the global Phase III OASIS trial of olorofim in patients with invasive aspergillosis, a life-threatening fungal infection that mainly affects immunocompromised patients.
After months of regulatory uncertainty, uniQure says the FDA will accept three-year Phase I/II data as the primary basis for an accelerated approval application for AMT-130.
WhiteLab GenomicsDelivering therapeutic genetic material safely to the correct target in the body is one of the big challenges of modern medicine. We talked to David Del Bourgo, CEO of WhiteLab Genomics, about how AI is helping design a new generation of vectors to tackle neurological diseases.
Kurma PartnersEuropean biotech is seeing both encouraging momentum and challenges. Innovation from European academia continues to inspire therapeutic concepts.
NIHWith a first $50 million tranche of its Series B financing and a commercial partnership with MEDICE, HMNC Brain Health has secured fresh capital for its depression programmes. The deal marks an important milestone for the Munich-based company – nearly a decade after it first set out to transform psychiatry through precision medicine.
Finnish biotech Aplagon has raised €4.8m to broaden Phase II development of its lead candidate APAC, a first-in-class antiplatelet and anticoagulant therapy for thrombo-inflammatory diseases. The financing will support a new Phase II clinical programme in arteriovenous fistula (AVF) maturation failure in patients with end-stage kidney disease.
Kos Biotechnology Partners has raised US$123m (€106m) for its inaugural global life sciences fund, marking a notable step for Greece’s still young biotechnology financing ecosystem.
CM4Cure. All Rights Reserved.CM4Cure is focused on substantially improving patient outcomes, improving medical device performance by incorporating drug delivery. Our technology redefines medical device coatings – converting passive barriers into active systems via a unique nanogel able to deliver multiple APIs. Initially focused on iv catheters – >2bn are used globally pa – the platform has potential to reduce infection and thrombosis across a swathe of medical devices
Sensorion has selected SENS-601, its gene therapy candidate for GJB2-related hearing loss, as its lead gene therapy program after filing clinical trial applications in France and Canada. The French biotech is discontinuing development of its OTOF-targeted therapy SENS-501, citing a changed competitive environment following the approval of Regeneron’s rival gene therapy.